Incyte Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Herve Hoppenot

Geschäftsführender

US$16.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.8%
Amtszeit als Geschäftsführer	11yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Herve Hoppenot im Vergleich zu den Einnahmen von Incyte verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$32m
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m

Vergütung im Vergleich zum Markt: HerveDie Gesamtvergütung ($USD16.66M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.70M).

Entschädigung vs. Einkommen: HerveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Herve Hoppenot (64 yo)

11yrs

Amtszeit

US$16,659,526

Vergütung

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Herve Hoppenot	CEO & Chairman	11yrs	US$16.66m	0.20% $ 26.6m
Pablo Cagnoni	President and Head of Research & Development	1.7yrs	US$16.57m	0.00087% $ 116.7k
Christiana Stamoulis	Executive VP & CFO	5.9yrs	US$5.08m	0.019% $ 2.6m
Barry Flannelly	Executive VP & GM of North America	9.6yrs	US$4.09m	0.0062% $ 831.7k
Steven Stein	Executive VP & Chief Medical Officer	9.8yrs	US$5.63m	0.0013% $ 178.4k
Thomas Tray	VP of Finance	2.8yrs	keine Daten	0.0041% $ 550.0k
Michael Morrissey	Executive VP & Head of Global Technical Operations	9yrs	keine Daten	0.019% $ 2.5m
Ben Strain	Head of Investor Relations	no data	keine Daten	keine Daten
Sheila Denton	Executive VP	1.3yrs	keine Daten	0.0023% $ 312.6k
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten
Paula Swain	Executive Vice President of Human Resources	22.4yrs	US$1.31m	0.030% $ 4.0m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0013% $ 171.7k

9.0yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: 0J9PDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (9 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Herve Hoppenot	CEO & Chairman	11yrs	US$16.66m	0.20% $ 26.6m
Jean-Jacques Bienaime	Independent Director	10yrs	US$478.76k	0.0080% $ 1.1m
Julian Baker	Independent Lead Director	23.2yrs	US$512.76k	0.14% $ 19.4m
Otis Brawley	Independent Director	3.3yrs	US$454.76k	0.0031% $ 410.5k
Jacqualyn Fouse	Independent Director	8yrs	US$466.26k	0.0073% $ 973.9k
Edmund Harrigan	Independent Director	5.1yrs	US$482.26k	0.0072% $ 968.5k
Katherine High	Independent Director	4.8yrs	US$454.76k	0.0042% $ 556.7k
Paul Clancy	Independent Director	10yrs	US$479.76k	0.0086% $ 1.2m
Susanne Schaffert	Independent Director	2.3yrs	US$444.76k	0.0015% $ 201.2k

8.0yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: 0J9PDie Vorstandsmitglieder gelten als erfahren (8 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/01/04 19:11
Aktienkurs zum Tagesende	2025/01/03 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Incyte Corporation wird von 54 Analysten beobachtet. 23 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Executive VP & GM of North America recently sold US$1.1m worth of stock

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Recent updates

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023)

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023)

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Executive VP & GM of North America recently sold US$1.1m worth of stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023)

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022)

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Incyte Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022)

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022)

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021)

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021)

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021)

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.